Drug Profile
Research programme: VEGF antagonists - Santen
Alternative Names: Nova 21012; Nova 21013Latest Information Update: 29 May 2013
Price :
$50
*
At a glance
- Originator Novagali Pharma
- Class
- Mechanism of Action Vascular endothelial growth factor A inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Age-related macular degeneration; Retinal disorders
Most Recent Events
- 29 May 2013 Discontinued - Preclinical for Age-related macular degeneration in France (Ophthalmic)
- 29 May 2013 Discontinued - Preclinical for Age-related macular degeneration in Israel (Ophthalmic)
- 29 May 2013 Discontinued - Preclinical for Retinal disorders in France (Ophthalmic)